I don't completely disagree with you, but you're contradicting yourself.
The company clarified previously released data, which is good. If you're going to release data it should be qualified to a reasonable degree. It's better for them to say thymoma than cancer patient.
On one hand you're suggesting the company is giving false hope. I've seen them make no such claims that would remotely encourage patients to skip second or third line therapies and use Kevetrin instead. They aren't hyping the drug to media outlets, or if they are then it isn't working. But on the other hand you're suggesting it would be appropriate for them to disseminate the information to hospitals for compassionate use? I'm sorry but actually encouraging physicians to use the drug is much worse than providing information to investors so that they don't discount the drug's progression. I trust the FDA to understand statistics and hazard ratios, not MDs.
The information was only released after the sp started falling after a hit piece. The same thing occurred previously with info about a single metastatic spleen lesion, at least in terms of release after a significant drop to sp. The pattern so far has been to not release any data, except when the company's ability to raise capital is significantly jeopardized, which also directly jeopardizes what at this point can only be labeled a potentially very important drug.
These n of 1 snippets were not released to hype the drug or artificially inflate the sp, they were released to prevent the sp from being artificially deflated.
Kevetrin should not be used outside of clinical trials until it demonstrates more compelling/significant efficacy and safety data, period.
People also shouldn't post misleading articles designed to artificially deflate the sp so that they can make a profit from shorting the stock.
A SA author is exploiting one of these, the company is not.
AI
Market Data 
Markets 
